Acute infusion reactions induced by monoclonal antibody therapy

Expert Rev Clin Immunol. 2011 Jan;7(1):55-63. doi: 10.1586/eci.10.90.


This article reports recent evidence on epidemiological data concerning monoclonal antibody (mAb) infusion-related anaphylaxis, as well as recent data on the correlation between mAb immunogenicity and safety profiles. Pathogenic mechanisms of mAb-related adverse reactions including hypersensitivity, IgE- and non-IgE-mediated events and cytokine release syndrome are also highlighted. Finally, the role of serum anti-mAb antibodies as markers to monitor the safety of such therapeutical compounds are extensively evaluated. The anaphylaxis occurring during therapy with the anti-TNF-α mAb infliximab, largely used in immune-mediated diseases, has been taken as a paradigm.

Publication types

  • Review

MeSH terms

  • Anaphylaxis / chemically induced*
  • Anaphylaxis / epidemiology*
  • Anaphylaxis / immunology
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects*
  • Drug Hypersensitivity / etiology*
  • Drug Hypersensitivity / immunology
  • Humans
  • Immunoglobulin E / blood
  • Immunoglobulin E / immunology
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / adverse effects*
  • Incidence
  • Infliximab
  • Infusions, Intravenous / adverse effects*
  • Tumor Necrosis Factor-alpha / immunology


  • Antibodies, Monoclonal
  • Immunologic Factors
  • Tumor Necrosis Factor-alpha
  • Immunoglobulin E
  • Infliximab